Nanobiotix Sa ADR (NBTX) has disclosed a new risk, in the Trade Secrets category.
Nanobiotix Sa ADR faces a pronounced business risk due to its heavy reliance on Janssen for the development and commercialization of its radioenhancer NBTXR3. The exclusive agreements grant Janssen comprehensive rights, limiting Nanobiotix’s ability to pursue other partnerships and necessitating successful collaboration for the company’s financial stability. Manufacturing obligations and the potential for Janssen to unilaterally terminate the agreements exacerbate these risks. Consequently, any disruption in this relationship could have a detrimental impact on Nanobiotix’s revenue and operational performance.
The average NBTX stock price target is $12.00, implying 103.05% upside potential.
To learn more about Nanobiotix Sa ADR’s risk factors, click here.
